Introduction {#s1}
============

Diabetes mellitus is a metabolic disorder which is associated by hyperglycemia with multiple disorders. A major metabolic defeat associated with diabetes is the failure of peripheral tissues in the body to utilize glucose that ultimately leads to chronic hyperglycemiaand further to other diabetes-related complications.^[@R1],[@R2]^ Moreover disturbances in lipid metabolism as a result of obesity, a secondary complication arising during diabetes, may further worsen during diabetic condition. The current diabetic drugs have designed to alleviate diabetes, but not to cure it; hence targeting drugs having multiple actions for therapy is encouraging. Many plant based foods and medicines are found to be the potential sources for hypoglycemic drugs which are well documented to treat diabetes in Indian system of medicines. Even more number of traditional medicinal plants merit evaluation of therapeutic potential. Traditionally, *Caralluma* species claimed to have antidiabetic properties, but there are only few scientific reports to prove the same.^[@R3],[@R4]^ *Caralluma umbellata* (*C. umbellata*) Haw (sub family Ascelpediaceae) belongs to *Caralluma* genus, distributed throughout the Indian subcontinent and widely used as vegetable. Pregnane glycosides such as carumbelloside-I to carumbelloside-V, and a flavone glycoside, luteolin-4'-O-neohesperidoside have been found to be major bioactive compounds in this species. The phytochemical study showed the presence of polyphenols suggesting it may have hypoglycemic activities,^[@R5]^ as the plant polyphenols are known to have hypoglycemic activities.^[@R6],[@R7]^ In the present study we aimed at exploring antidiabetic potential of *C. umbellata* by evaluating its effect on glucose uptake in rat myotubes, inhibitory property against digestive enzymes, namely, α-amylase and pancreatic lipase.

Materials and methods {#s2}
=====================

Collection and preparation of plant material {#s2-1}
--------------------------------------------

The plant material was collected from Tirupathy, Andhra Pradesh, India during May 2011. The plant material was authenticated by Dr. Madava Chetty, S .V University, Tirupathi and confirmed by comparing against the housed authenticated specimen. Aerial part was shade dried, powdered and extracted with methanol (MCU), water (ACU) successively and another set of powdered material was extracted with methanol: water (60:40) (HCU) using soxhlet apparatus. Then, MCU was dissolved in water and further fractionated by liquid-liquid extraction with ethyl acetate (EACU), chloroform (CHCU), n-butanol (BUCU) and remaining residue (RMCU). The extracted materials and separated fractions were dried under reduced pressure by rotary evaporator (Superfit, India).

In vitro cytotoxicity in L6 cell line {#s2-2}
-------------------------------------

The cytotoxicity of test extracts and fractions were determined by MTT assay to select the non-toxic doses for glucose uptake studies.Briefly the cells were seeded in microtitre plates at a density of 2×10^4^ cells/well, after attaining confluence the test extracts and fractions were added and incubated for 24 h. Percentage cytotoxicity was then determined as described earlier.^[@R8]^

Glucose uptake study of C.umbellata extracts in cultured myotubes {#s2-3}
-----------------------------------------------------------------

*In vitro* glucose uptake potentials of test extracts and fractions were performed in differentiated myotubes as described earlier with slight modification.^[@R9]^ Briefly, myotubes were serum deprived overnight, followed by incubation with glucose free medium for 1 h. The cells were treated with test extracts and fractions (500‏ µg/ml) and insulin (1‏ IU/ml) for 20 min followed by addition of 1 M glucose solution and incubated for 20 min at room temperature. At the end of the experiment cell bound glucose was measured by GOD-POD method using biochemical kit (ERBA diagnostics, Germany) at 505 nm. In the next step, bioactive sample (MCU) was evaluated for its glucose uptake potential in presence and absence of wortamannin (Sigma Aldrich, India), a PI 3-kinase inhibitor which was used to access the involvement of extract on translocation of GLUT4 to understand the mechanism of action.

Alpha amylase inhibition {#s2-4}
------------------------

The α-amylase (Hi media, Mumbai) inhibition capacity was determined by the earlier described method with minor modifications with starch as substrate.^[@R10]^ Briefly, inhibitory activity was determined by incubating extracts (MCU, ACU and HCU) with amylase followed by starch and Dinitrosalicyclic acid reagent to estimate the residual activity of enzyme by colorimetric estimation at 540 nm. Acarbose was used as positive control. Percentage inhibition was calculated by comparing against control reaction without test sample and IC~50~ values were determined by the logarithmic regression analysis.

Porcine pancreatic lipase inhibition {#s2-5}
------------------------------------

Porcine pancreatic lipase (PPL type II, Sigma Aldrich, India) activity was measured using *p*-nitrophenyl butyrate (*p*-NPB) (Sigma Aldrich, India) as a substrate as described earlier.^[@R11]^ Briefly, inhibitory activity was determined by incubating extracts (MCU, ACU and HCU) with PPL followed by *p*-NPB. The percentage of residual activity of PPL was determined for the test samples by comparing against control reaction without test sample. Orlistat was used as a positive control. IC~50~ values were determined by the logarithmic regression analysis.

Statistical analysis {#s2-6}
--------------------

Statistical comparisons were tested using One-Way ANOVA and post Dunnet's test and the differences were considered significant at the level of *p*\<0.05.

Results {#s3}
=======

In vitro cytotoxicity {#s3-1}
---------------------

The cytotoxicity of test extracts and fractions was found to be moderate with CTC~50~ values ranging between 600 to \>1000 µg/ml; hence for glucose uptake studies, a safe concentration of 500‏ µg/ml was fixed.

Glucose uptake study {#s3-2}
--------------------

Among the extracts tested for glucose uptake, MCU showed a significant enhancement in glucose uptake with 66±2.58% uptake over basal control ([Fig. 1](#F1){ref-type="fig"}, *p*\<0.001). Other extracts, ACU and HCU showed moderate enhancements in glucose uptake with 8.2±1.49 and 16.3±1.3, respectively; hence MCU was further fractionated to obtain four fractions. Fractions of MCU also exhibited an increase in glucose uptake and among them, CHCU exhibited a significant uptake ([Fig. 1](#F1){ref-type="fig"}) with 56±2.40% uptake over basal control and the rest of fractions showed moderate activity.
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In the next set of experiments, the potent extract MCU was evaluated to understand the mechanism of action and experiments were performed in presence and absence of wortmannin. In presence of wortmannin, the glucose uptake by MCU was found to be at lower level with 39±2.09% over basal control whereas in absence of wortmannin, MCU exhibited 58±7.97% uptake. Insulin (INS) also showed a significant reduction in uptake in the presence of wortmannin as shown in [Fig. 2](#F2){ref-type="fig"}.
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Alpha amylase and pancreatic lipase inhibition {#s3-3}
----------------------------------------------

The extracts (MCU, ACU and HCU) were also evaluated for their activity against digestive enzymes and all the three extracts showed inhibitory action against both alpha amylase and pancreatic lipase in a dose dependent manner. Among the extracts, MCU showed the highest activity at 1000 µg/ml with the IC~50~ found to be at 853±10.41‏ µg/ml. The standard acarbose showed potent inhibition with the IC~50~ of 323.97±4.91‏ µg/ml against alpha amylase ([Table 1](#T1){ref-type="table"}). Against pancreatic lipase, HCU showed a better activity with the IC~50~ which was found to be at \>1000‏ µg/ml and standard orlistat IC~50~ was found to be 0.15±0.03‏ µg/ml ([Table 1](#T1){ref-type="table"}).

###### Alpha amylase and pancreatic lipase inhibition

  ------------ ----------------- ------------------------- -------------------------------- ------------------------------------
  **Sl. No**   **Test sample**   **Test concentration**\   **% Alpha amylase inhibition**   **% Pancreatic lipase Inhibition**
                                 **(µg/ml)**                                                

  1            MCU               1000                      52.27±1.12                       21.6±0.61

  500          40.68±1.24        7.1±3.74                                                   

  250          39.23±1.73        4.3±2.13                                                   

  2            ACU               1000                      37.08±1.09                       26.3±03.20

  500          34.59±1.01        22.5±02.58                                                 

  250          31.18±1.93        19.2±01.87                                                 

  3            HCU               1000                      45.33±0.90                       29.6±2.49

  500          39.41±5.47        20.6±1.60                                                  

  250          37.13±4.13        15.0±2.36                                                  

  4            Acarbose          1000                      68.00±1.17                       ND

  500          52.07±2.39        ND                                                         

  250          44.49±1.69        ND                                                         

  5            Orlistat          10                        ND                               85.0±0.82

  5            ND                81.5±0.25                                                  

  2.5          ND                80.7±1.62                                                  
  ------------ ----------------- ------------------------- -------------------------------- ------------------------------------

Result represented in Mean±SD (n=3), MCU**-**methanolic extract, ACU-aqueous extract, HCU- hydro methanolic extract, ND- not determined.

Discussion {#s4}
==========

*C. umbellata* has been used as a traditional medicinal plant for treating stomach disorders and abdominal pains.^[@R12]^ Very few attempts were made to evaluate its pharmacological efficacy. Recent scientific reports have suggested that this plant has hepatoprotective, antinociceptive and anti-inflammatory properties,^[@R12],[@R5]^ however other traditional claims and possible pharmacological benefits of *C. umbellata* were not been explored. Other species from the same genus were reported to have different biological properties, which suggest the therapeutic potential of *caralluma* genus. In present study, *C. umbellata* showed promising antidiabetic properties, especially the methanolic extract of whole plant (MCU) exhibited potential glucose uptake enhancement in myotubes, hence this extract may regulate the blood glucose level.^[@R9]^ Comparable significant activities were also reported from other medicinal plants such as *A. cepa, Z .officinale*, *G. lucidum* showing promising activity up to 95% glucose uptake over control, hence suggesting the potential use of medicinal plants for diabetic treatment.^[@R13],[@R14]^ ACU and HCU showed moderate uptake comparable to MCU which the differences in uptake may be due to the presence of certain class of phytochemicals. As stated earlier, polyphenols have been reported to have antidiabetic effect and such polyphenols have been found highly in methanolic extracts as suggested by various authors,^[@R15]^ however the exact chemical constituents which may be responsible for hypoglycemic effect of extracts still remains speculative. Previous studies also support this data where alcoholic extracts from different species of similar genus, *C. attenuata, C. fimbriata* and *C. sinaica*, had shown potent antidiabetic properties.^[@R4],[@R6]^

Glucose uptake in skeletal muscle through GLUT4 translocation is an important step in controlling blood glucose level. Other way PI3 kinase regulates GLUT4 translocation and plays a major role in blood glucose management. Thus to understand the mechanism of action, experiments were performed in presence and absence of a specific blocker of PI3 kinase, wortmannin. The observed difference was marginal in presence of wortamannin, hence the uptake from MCU may be partially through PI3 kinase mediated GLUT4 translocation and may also act at multiple pathways in enhancing uptake of glucose in myotubes.^[@R16],[@R17]^

Inhibiting the target enzyme responsible for glucose metabolism is one among the key approaches in controlling diabetes. Alpha amylase is one among such enzymes involved in carbohydrate metabolism. Inhibition of amylase may lead to delay in glucose metabolism and hence a net reduction of available glucose for absorption and thus controlling glucose level.^[@R18]-[@R20]^ Apart from targeting enzymes related to carbohydrate metabolism, another enzyme responsible for the hydrolysis of total dietary fats is the pancreatic lipase which breaks down fats to triacylglycerols.^[@R21]^ Inhibiting pancreatic lipase reflects in reduced absorption of monoglycerides and fatty acids.^[@R22],[@R23]^ Hence pancreatic lipase inhibition is found to be a valuable target for the treatment of diet-induced hyperglycemia in humans, thus indicating its beneficial role in managing obesity related complications occurring in diabetes.^[@R24]^ Interestingly, MCU also inhibited both pancreatic lipase and alpha amylase *in vitro* in a dose dependent manner. Hence the observed inhibitory activity may be due to polyphenols present in the extracts as suggested by various authors.^[@R24],[@R25]^ These observations indicate that MCU has got a potential to act at multiple points *viz* stimulating glucose uptake and inhibiting alpha amylase and pancreatic lipase.

Conclusion {#s5}
==========

The glucose uptake activity of *C. umbellata* may be partially attributed to the GLUT4 translocation as well as to other pathways which has to be studied thoroughly by gene expression studies and also it may be necessary to investigate type of mechanism involved in inhibition of amylase and pancreatic lipase by kinetic studies. Furthermore identifying active phytoconstituents responsible for such activities which can strengthen the use for therapeutic applications are in progress in our laboratory.
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